{"organizations": [], "uuid": "b4ff9ee1989f3c543f1de07a71338549af8e53f3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-heat-biologics-interim-results-fro/brief-heat-biologics-interim-results-from-phase-2-study-investigating-hs-110-in-combination-with-anti-pd-1-idUSFWN1QI0T6", "country": "US", "domain_rank": 408, "title": "BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.901, "site_type": "news", "published": "2018-02-28T20:05:00.000+02:00", "replies_count": 0, "uuid": "b4ff9ee1989f3c543f1de07a71338549af8e53f3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-heat-biologics-interim-results-fro/brief-heat-biologics-interim-results-from-phase-2-study-investigating-hs-110-in-combination-with-anti-pd-1-idUSFWN1QI0T6", "ord_in_thread": 0, "title": "BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "squibb co", "sentiment": "negative"}, {"name": "brief-heat biologics", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Bristol-Myers Squibb Co:\n* HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS‘S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB\n* HEAT BIOLOGICS SAYS COMBINATION OF HS-110 AND NIVOLUMAB WAS WELL TOLERATED - SEC FILING\n* HEAT BIOLOGICS - IN PHASE 2 CLINICAL TRIAL OF HS-110 AND NIVOLUMAB, OVERALL RESPONSES APPEARED DURABLE AND LONG LASTING‍​ Source text ( bit.ly/2BTjnp7 ) Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["http://bit.ly/2BTjnp7", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-28T20:05:00.000+02:00", "crawled": "2018-03-01T21:08:47.006+02:00", "highlightTitle": ""}